Mithra Pharmaceuticals will postpone the publication of its Annual Report 2023 (originally scheduled for 30 April 2024) as it was prepared based on a going concern assumption. Instead, considering the recent events, an annual report will be prepared and published for Mithra reflecting a situation "in discontinuity" at a later date, which will be announced in a subsequent communication.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.216 EUR | -1.82% | -.--% | -82.78% |
06-11 | Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. acquired Neuralis and Estetra from Mithra Pharmaceuticals SA. | CI |
05-28 | Mithra Delays AGM Amid Monetization Process | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-82.78% | 15.98M | |
+2.99% | 94.76B | |
-3.68% | 37.58B | |
-9.56% | 33.3B | |
+75.35% | 27.92B | |
-13.67% | 15.85B | |
-3.69% | 13.79B | |
-12.31% | 11.51B | |
+188.83% | 10.9B | |
-53.94% | 9.27B |
- Stock Market
- Equities
- MITRA Stock
- News Mithra Pharmaceuticals S.A.
- Mithra Pharmaceuticals to Postpone the Publication of Its Annual Report 2023